Articles

Employers slow to act on health reform

Even though employers expect the U.S. Supreme Court to strike down at least some of the 2010 health reform law later this month, few are actually doing any contingency planning.

Read More

Orthopedic startups attracting big money

The Warsaw area is well-known as the home of gigantic orthopedic implant companies and their suppliers. But now a handful of startups have been able to raise nearly $25 million in equity investments despite the recession—putting a bit more fuel into a fairly stagnant entrepreneurial sector.

Read More

Price hikes offset slower health care use

Newly available data from private health insurance plans show that price hikes by hospitals, doctors and drug companies have kept employer spending rising recently even as their employees and dependents have moderated their consumption of health care services.

Read More

Physician buyouts bruising hospitals

As St. Vincent Health has nearly doubled the number of physicians it employs over the past two years, the losses on those practices have mounted. And the same thing is happening at all the major Indianapolis hospital systems, as all have spent the past four years aggressively acquiring physician practices.

Read More

FDA’s $6.4B drug review fee plan passes Senate

The U.S. Senate voted to let regulators collect on a $6.4 billion fee agreement struck with Indianapolis-based Eli Lilly and Co., Medtronic Inc. and other companies to fund reviews of new drugs and medical devices through 2017.

Read More

Justices grill both sides in IU Health case

Much of the nearly 45 minutes of arguments and questioning on May 10 involved the justices and the lawyers for both parties trying unsuccessfully to apply various scenarios from the retail world of commerce to health care pricing.

Read More

Cancer tools help Roche with Alzheimer’s drug

Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.

Read More

Lilly: Forget Alzheimer’s; think diabetes

For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.

Read More